Evidence map›Paper›PMID 33381038›Full record

ArticleFrontiers in pharmacology2020

TRPM7 Induces Tumorigenesis and Stemness Through Notch Activation in Glioma.

Jingwei Wan, Alyssa Aihui Guo, Pendelton King, Shanchun Guo, Talib Saafir, Yugang Jiang, Mingli Liu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. The Role of TRPM7 in Oncogenesis.International journal of molecular sciences · 2024
    Review
  11. Review
  12. Article
  13. Review
  14. New Insights into TRP Ion Channels in Stem Cells.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Jingwei WanDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Alyssa Aihui GuoUniversity of South Carolina SOM Greenville, Greenville, SC, United States.
Pendelton KingDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Shanchun GuoDepartment of Chemistry, Xavier University, New Orleans, LA, United States.
Talib SaafirNeuroscience Institute, Morehouse School of Medicine, Atlanta, GA, United States.
Yugang JiangDepartment of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Mingli LiuDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Morehouse School of Medicine · USCentral South University · CNSecond Xiangya Hospital of Central South University · CNUniversity of South Carolina · USXavier University · US

Funding

TRPM7 induces tumorigenesis and stemness through Notch activation in gliomaSC1GM144021 · NIGMS · MOREHOUSE SCHOOL OF MEDICINE · PI LIU, MINGLI · 2022 to 2025
$1.4M
The Role of TRPM7 in Progression of Malignant GliomaSC3GM121230 · NIGMS · MOREHOUSE SCHOOL OF MEDICINE · PI LIU, MINGLI · 2018 to 2021
$426k
NIGMS NIH HHS SC1 GM144021NIGMS NIH HHS SC3 GM121230
6 · The paper itself

Abstract

We have reported that transient receptor potential melastatin-related 7 (TRPM7) regulates glioma stem cells (GSC) growth and proliferation through Notch, STAT3-ALDH1, and CD133 signaling pathways. In this study, we determined the major contributor(s) to TRPM7 mediated glioma stemness by further deciphering each individual Notch signaling. We first determined whether TRPM7 is an oncotarget in glioblastoma multiforme (GBM) using the Oncomine database. Next, we determined whether TRPM7 silencing by siRNA TRPM7 (siTRPM7) induces cell growth arrest or apoptosis to reduce glioma cell proliferation using cell cycle analysis and annexin V staining assay. We then examined the correlations between the expression of TRPM7 and Notch signaling activity as well as the expression of GSC markers CD133 and ALDH1 in GBM by downregulating TRPM7 through siTRPM7 or upregulating TRPM7 through overexpression of human TRPM7 (M7-wt). To distinguish the different function of channel and kinase domain of TRPM7, we further determined how the α-kinase-dead mutants of TRPM7 (α-kinase domain deleted/M7-DK and K1648R point mutation/M7-KR) affect Notch activities and CD133 and ALDH1 expression. Lastly, we determined the changes in TRPM7-mediated regulation of glioma cell growth/proliferation, cell cycle, and apoptosis by targeting Notch1. The Oncomine data revealed a significant increase in TRPM7 mRNA expression in anaplastic astrocytoma, diffuse astrocytoma, and GBM patients compared to that in normal brain tissues. TRPM7 silencing reduced glioma cell growth by inhibiting cell entry into S and G2/M phases and promoting cell apoptosis. TRPM7 expression in GBM cells was found to be positively correlated with Notch1 signaling activity and CD133 and ALDH1 expression; briefly, downregulation of TRPM7 by siTRPM7 decreased Notch1 signaling whereas upregulation of TRPM7 increased Notch1 signaling. Interestingly, kinase-inactive mutants (M7-DK and M7-KR) resulted in reduced activation of Notch1 signaling and decreased expression of CD133 and ALDH1 compared to that of wtTRPM7. Finally, targeting Notch1 effectively suppressed TRPM7-induced growth and proliferation of glioma cells through cell G1/S arrest and apoptotic induction. TRPM7 is responsible for sustained Notch1 signaling activation, enhanced expression of GSC markers CD133 and ALDH1, and regulation of glioma stemness, which contributes to malignant glioma cell growth and invasion.

Indexed as

Aldehyde dehydrogenase 1apoptosisCD133cell cyclegliomamolecular targetsTRPM7

Identifiers

PMID33381038
PMCPMC7768084
OpenAlexW3111521526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.